Related Experiment Videos
[The study of relationship between c-erbB2 expression and cytoimmunology in ovarian carcinoma and its antisense
Abstract:
The relationship between c-erbB2 expression and cytoimmunology in ovarian carcinoma cell lines was studied; the synthesized and modified c-erbB2 antisense oligodeoxynucleotide was tested for its ability to reduce over-expression of c-erbB2. The results showed that over-expression of c-erbB2 in ovarian carcinoma could induce resistance to tumor necrosis factor (TNF) and lymphokine activated killer (LAK) cells but had no effect on H2O2; c-erbB2 antisense oligodeoxynucleotide could specifically reduce the over-expression of c-erbB2 and increase the sensitivity of ovarian cancer targets to lysis by TNF and LAK cells.
Insights
Over-expression of c-erbB2 in ovarian cancer increases resistance to immune cells. C-erbB2 antisense oligodeoxynucleotide therapy can overcome this resistance, enhancing cancer cell lysis by tumor necrosis factor (TNF) and lymphokine-activated killer (LAK) cells.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Context:
- Ovarian carcinoma is a complex malignancy with varied responses to immunotherapy.
- The c-erbB2 oncoprotein plays a significant role in cancer progression and treatment resistance.
- Understanding the interplay between c-erbB2 and immune cell-mediated cytotoxicity is crucial for developing novel therapeutic strategies.
Purpose:
- To investigate the functional relationship between c-erbB2 expression and cellular immunity in ovarian cancer.
- To evaluate the efficacy of a synthesized c-erbB2 antisense oligodeoxynucleotide in modulating c-erbB2 over-expression and enhancing anti-tumor immunity.
Summary:
- Over-expression of c-erbB2 in ovarian carcinoma cell lines was found to confer resistance to tumor necrosis factor (TNF) and lymphokine-activated killer (LAK) cells.
- c-erbB2 over-expression did not affect sensitivity to hydrogen peroxide (H2O2)-induced cytotoxicity.
- The developed c-erbB2 antisense oligodeoxynucleotide specifically reduced c-erbB2 over-expression.
- This reduction in c-erbB2 led to increased sensitivity of ovarian cancer cells to lysis by TNF and LAK cells.
Impact:
- This study highlights c-erbB2 as a potential therapeutic target for overcoming immune resistance in ovarian cancer.
- The findings suggest that c-erbB2 antisense oligodeoxynucleotide therapy holds promise for enhancing the effectiveness of immunotherapy in ovarian cancer patients.
- This research contributes to the development of targeted therapies aimed at improving patient outcomes in ovarian carcinoma.